Calamos Advisors LLC Acquires 13,120 Shares of Stryker Corporation $SYK

Calamos Advisors LLC increased its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 112,881 shares of the medical technology company's stock after acquiring an additional 13,120 shares during the quarter. Calamos Advisors LLC's holdings in Stryker were worth $39,674,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Cypress Asset Management Inc. TX bought a new position in Stryker during the fourth quarter worth about $291,000. Mendel Money Management grew its stake in Stryker by 31.4% during the fourth quarter. Mendel Money Management now owns 1,803 shares of the medical technology company's stock worth $634,000 after buying an additional 431 shares in the last quarter. Segment Wealth Management LLC grew its stake in Stryker by 2.1% during the fourth quarter. Segment Wealth Management LLC now owns 53,289 shares of the medical technology company's stock worth $18,730,000 after buying an additional 1,105 shares in the last quarter. Golden Reserve Retirement LLC acquired a new stake in Stryker during the fourth quarter worth about $221,000. Finally, DecisionPoint Financial LLC grew its stake in Stryker by 4,383.3% during the fourth quarter. DecisionPoint Financial LLC now owns 538 shares of the medical technology company's stock worth $189,000 after buying an additional 526 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 0.5%

SYK opened at $327.84 on Friday. The company's 50 day moving average is $349.77 and its 200-day moving average is $358.34. Stryker Corporation has a 1-year low of $319.32 and a 1-year high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The company has a market cap of $125.56 billion, a P/E ratio of 39.03, a PEG ratio of 1.93 and a beta of 0.92.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts' consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same period last year, the company posted $4.01 EPS. The firm's quarterly revenue was up 11.4% compared to the same quarter last year. Equities research analysts predict that Stryker Corporation will post 14.92 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Stryker's dividend payout ratio (DPR) is presently 41.90%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.60% of the company's stock.

Wall Street Analyst Weigh In

SYK has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research note on Saturday, April 18th. Needham & Company LLC increased their price objective on shares of Stryker from $448.00 to $454.00 and gave the stock a "buy" rating in a research note on Friday, January 30th. Jefferies Financial Group reiterated a "buy" rating and set a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Raymond James Financial upgraded shares of Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 price objective on the stock in a research note on Tuesday, January 6th. Finally, William Blair reiterated an "outperform" rating on shares of Stryker in a research note on Thursday, March 5th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $421.11.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.